[{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Merdury Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Interferon Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Ainos"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Lind Partners"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ainos \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Ainos

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for patients with Sjögren's syndrome.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 11, 2024

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 17, 2024

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The financing will be used to advance company's products including VELDONA (interferon alfa) which binds to type I interferon receptors (IFNAR). It is being evaluated for thrombocytopenia.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 07, 2024

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $9.0 million

                          Deal Type : Financing

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated in phase 1 clinial trials for the treatment of mild COVID-19 symptoms.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 05, 2024

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 24, 2024

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Hematology

                          Highest Development Status : IND Enabling

                          Sponsor : Lind Partners

                          Deal Size : $1.7 million

                          Deal Type : Financing

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 21, 2023

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona is a low-dose oral interferon formulation investigated as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug c...

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 18, 2023

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 14, 2023

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Merdury Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Veldona, a low-dose oral interferon-alpha formulation to boost the human body’s frontline defenses against disease and infection. IFN-α is a key component of our body’s innate immune response to viral infection. Most cells in the body will produce i...

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 31, 2022

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : A pre-clinical animal study we conducted since March of this year validated the effectiveness of our low-dose oral Veldona (interferon) therapy to protect against COVID-19.

                          Brand Name : Veldona

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 24, 2022

                          Lead Product(s) : Interferon Alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank